During a 15-year follow-up in 1,040,341 drug-naive patients with T2DM, we observed a decreased risk for LC among all non-insulin antidiabetic drugs when compared with insulin except for alpha-glucosidase inhibitors. The gene discussed is INS; the disease is type 2 diabetes mellitus.